Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenezumab in Prodromal to Mild Alzheimer's Disease
NCT03114657Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2017
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of crenezumab in Alzheimer's disease (AD), sponsored by Roche. Started Mar 2017; status: terminated.
02
Drugs
crenezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03114657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114657.